Evaluation of treatment effectiveness of asthma/COPD overlap in patients with and without obesity considering the polymorphic variant C646G of the NR3C1 gene (rs41423247)

The Aim. current study evaluates the possibility of using C646G polymorphic variant NR3C1 gene (rs41423247) for personalized administration combination therapy with inhaled glucocorticosteroids (iGCs) and long-acting β2-agonists in patients asthma/COPD overlap (ACO) without obesity.Material methods. Forty ACO were included (17 BMI < 30 23 obesity (BMI ≥ 30) to received combined treatment use prolonged β 2 -agonists ICS. CAT test, asthma control questionnaire (Asthma Control Questionnaire-5 - ACQ-5) BODE index used analyze outcomes, genetic markers being considered one month after began. To assess distribution genotypes alleles between groups, we two-tailed Pearson chi-square test (χ2) odds ratio (OR) 95% confidence interval (CI). Mathematical processing obtained data was performed SPSS (Statistical Package Social Science Statistics) 16,0 programs.Results. analysis results revealed that a significant frequency GG genotype (80,00%) observed group who noted progressive deterioration symptom according which significantly differed [χ²=17,293; p˂0,001] from positive dynamics, whom did not occur at all. In no improvement on scale, rate G allele 0,96, C 0,44; dynamics these numbers 0,4 1, respectively [χ²=7,721; p=0,006; BP=5,000; CI: 1,547-16,163]. analyzing number points ACQ-5 comparable those when evaluated. found 50,00% negative or complete absence index, compared 12,5% [χ2=5,943, р=0,015; ВР=7,000 (95 % ДІ: 1,300-37,705)]. obesity, 94,44% absent carriers [χ2=8,074, р=0,005], whereas normal/overweight body weight, all had [χ2=6,679; р=0,016]. 59,1% but any patient [χ2=12,472, р˂0,001; ВР=24,556 2,752-219,100)]. Among studied, identified 14 people (rs41423247), 13 (92,85%) zero condition ICS agonists, estimate. When changes non-obese (BMI˂30) studied + regimen used, four seventeen dynamics: two CG [χ2=3,767, р=0,05]. presence genotype, (BMI≥30) experienced course disease response prescribed treatment. Simultaneously, there same [χ2=5,856, р=0,016].Conclusions. study's findings show is higher than weight. associated application 2-agonists, can serve as prognostic marker assessing risk lack effect this scheme prior its initiation ACO, particularly comorbidities.